推荐产品
产品名称
Camptothecin, 10-Hydroxy-, Camptotheca acuminata, A cell-permeable powerful DNA topoisomerase I inhibitor.
质量水平
方案
≥95% (HPLC)
表单
powder
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
颜色
pale yellow
溶解性
DMSO: 5 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
[n]21c(cc5c([c]2=O)COC(=O)C5(O)CC)c3nc4c(cc3C1)cc(cc4)O
InChI
1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3
InChI key
HAWSQZCWOQZXHI-UHFFFAOYSA-N
一般描述
A cell-permeable powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.
A cell-permeable, powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Inhibits the proliferation of hepatoma HepG2, Bcl-7402 and Bcl-7404 cells in a dose-dependent manner. Has selective inhibitory effect on the phosphorylation of histones H1 and H3, but is less effective on other histones.
生化/生理作用
Cell permeable: yes
Primary Target
DNA topoisomerase I
DNA topoisomerase I
Product does not compete with ATP.
Reversible: no
警告
Toxicity: Irritant (B)
重悬
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
其他说明
Zhang, X.W., et al. 1999. Anticancer Drugs.10, 569.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - Muta. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Mengfan Tang et al.
Nucleic acids research, 49(13), 7476-7491 (2021-07-02)
Poly (ADP-ribose) polymerase inhibitor (PARPi)-based therapies initially reduce tumor burden but eventually lead to acquired resistance in cancer patients with BRCA1 or BRCA2 mutation. To understand the potential PARPi resistance mechanisms, we performed whole-genome CRISPR screens to discover genetic alterations
Venugopal R Bovilla et al.
Biomedicines, 9(9) (2021-09-29)
Nuclear factor erythroid-2 related factor-2 (Nrf2) is an oxidative stress-response transcriptional activator that promotes carcinogenesis through metabolic reprogramming, tumor promoting inflammation, and therapeutic resistance. However, the extension of Nrf2 expression and its involvement in regulation of breast cancer (BC) responses
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门